HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Cytokinetics and raised the price target from $90 to $120, indicating a positive outlook for the company's stock.
October 09, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Cytokinetics and increased the price target from $90 to $120, suggesting confidence in the company's future performance.
The increase in the price target from $90 to $120 by HC Wainwright & Co. reflects a strong positive sentiment towards Cytokinetics' future performance. This is likely to lead to a short-term increase in the stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100